Rachel Ballinger
Biographic Data
| ID | 167726 |
|---|---|
| NAME | Rachel Ballinger |
| GIVEN NAMES | Rachel |
| FAMILY NAME | Ballinger |
| SIGNATURE | BALLINGER R |
| AFFILIATIONS | Brighton and Sussex Medical School |
| VERIFIED | No |
| TOTAL WORKS | 5 |
| TOTAL CITATIONS | 17 |
| WORKS AS AUTHOR | 5 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2011 |
| LATEST PUBLICATION YEAR | 2012 |
| H-INDEX | 2 |
The emergence of the genetically engineered animal models in carcinogenic risk assessment of pharmaceuticals
In this article, we explain the emergence of new short-term tests for carcinogenicity involving genetically engineered animals for the purposes of pharmaceutical regulation. Drawing on some long-standing theories of technological innovation, we argue that the alteration of carcinogenic risk assessment of pharmaceuticals, which occurred from 1998, did not result solely, or perhaps even mainly, from internal logical and technical developments in th…
The Neoliberal Regulatory State, Industry Interests, and the Ideological Penetration of Scientific Knowledge
It is argued that neoliberal political ideology has redefined the regulatory state to have greater convergence of interests and goals with the pharmaceutical industry than previously, particularly regarding acceleration and cost reduction of drug development and regulatory review. Consequently, the pharmaceutical industry has been permitted to set the agenda about how shorter term and cheaper alternative carcinogenicity testing systems are invest…
Science, politics, and health in the brave new world of pharmaceutical carcinogenic risk assessment
Power, expertise and the limits of representative democracy
The slide to pragmatism
This paper reports on a qualitative study of UK mental health practitioners’ experiences of working with the contested condition, dangerous and severe personality disorder (DSPD). Our interviews focused on the issues of treatability, risk assessment and decision-making in multi-disciplinary teams. We discuss the approach of values-based medicine (VBM) as a useful framework for interpreting the data: respondents cited both explicit values (based o…
The Neoliberal Regulatory State, Industry Interests, and the Ideological Penetration of Scientific Knowledge
It is argued that neoliberal political ideology has redefined the regulatory state to have greater convergence of interests and goals with the pharmaceutical industry than previously, particularly regarding acceleration and cost reduction of drug development and regulatory review. Consequently, the pharmaceutical industry has been permitted to set the agenda about how shorter term and cheaper alternative carcinogenicity testing systems are invest…
Science, politics, and health in the brave new world of pharmaceutical carcinogenic risk assessment
The slide to pragmatism
This paper reports on a qualitative study of UK mental health practitioners’ experiences of working with the contested condition, dangerous and severe personality disorder (DSPD). Our interviews focused on the issues of treatability, risk assessment and decision-making in multi-disciplinary teams. We discuss the approach of values-based medicine (VBM) as a useful framework for interpreting the data: respondents cited both explicit values (based o…
Power, expertise and the limits of representative democracy
The slide to pragmatism
This paper reports on a qualitative study of UK mental health practitioners’ experiences of working with the contested condition, dangerous and severe personality disorder (DSPD). Our interviews focused on the issues of treatability, risk assessment and decision-making in multi-disciplinary teams. We discuss the approach of values-based medicine (VBM) as a useful framework for interpreting the data: respondents cited both explicit values (based o…
The emergence of the genetically engineered animal models in carcinogenic risk assessment of pharmaceuticals
In this article, we explain the emergence of new short-term tests for carcinogenicity involving genetically engineered animals for the purposes of pharmaceutical regulation. Drawing on some long-standing theories of technological innovation, we argue that the alteration of carcinogenic risk assessment of pharmaceuticals, which occurred from 1998, did not result solely, or perhaps even mainly, from internal logical and technical developments in th…
The Neoliberal Regulatory State, Industry Interests, and the Ideological Penetration of Scientific Knowledge
It is argued that neoliberal political ideology has redefined the regulatory state to have greater convergence of interests and goals with the pharmaceutical industry than previously, particularly regarding acceleration and cost reduction of drug development and regulatory review. Consequently, the pharmaceutical industry has been permitted to set the agenda about how shorter term and cheaper alternative carcinogenicity testing systems are invest…
Science, politics, and health in the brave new world of pharmaceutical carcinogenic risk assessment
Biomedical Ethics and Regulation (4 works) · Law (4 works) · Medicine (4 works) · Political science (4 works) · Politics (4 works) · Business (3 works) · Law (3 works) · Pharmaceutical industry (3 works) · Biology (2 works) · Biotechnology and Related Fields (2 works)